

# Informing fresh versus standard Issue red cell management

<b>Submission date</b> 23/11/2011	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 16/02/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 01/03/2019	<b>Condition category</b> Haematological Disorders	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Transfusion of red blood cells is life-saving, but recent data suggests that transfusion of stored blood may also cause some harm. Transfusion of red blood cells stored for up to 42 days is standard medical practice. Recent studies have suggested the changes that develop during red blood cell storage might contribute to increased risk in some patients, but the results have generated significant controversy. In order to resolve the controversy, several studies are currently underway in very specific patient populations (critical care patients, patients undergoing cardiac surgery) comparing very fresh blood (less than 8 to 10 days of storage, with standard issue blood. This study will include all hospital patients receiving transfusion and does not use a specific storage age to define fresh blood; hence, it will provide information that will apply to all transfused patients. This study aims to determine the effect on in-hospital death rates of transfusing the freshest available blood compared with standard-issue blood.

### Who can participate?

All adults (18 years of age or older) patients admitted to the hospital who will receive a transfusion during their stay are potentially eligible for the study.

### What does this study involve?

The participant will not be contacted during this study. The decision to transfuse is determined by the patient's doctor. Once the ward orders the blood, the Transfusion Medicine Service will randomly allocate the patient to receive either the freshest available or standard-issue blood. The patient's data will be collected electronically. An information brochure will be distributed to the patient so they are made aware of the study.

### What are the possible benefits and risks of participating?

As of yet, there are no direct known benefits for the participating patients. Future societal benefits may occur from this study depending on the study findings. There are no added risks of participating in this study. The decision to transfuse a patient happens independently of the study.

### Where is the study run from?

The study is run from the McMaster Transfusion Medicine Program at McMaster University in

Hamilton, Canada. Patients are recruited from Hamilton General Hospital (Canada), Juravinski Hospital (Canada), Flinders Medical Centre (Australia), St Joseph's Healthcare in Hamilton (Canada) and the Cleveland Clinic (USA).

When is the study starting and how long is it expected to run for?  
January 2012 to November 2015

Who is funding the study?  
Canadian Institutes of Health Research (CIHR) (Canada)

Who is the main contact?  
Rebecca Barty  
bartyr@mcmaster.ca

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Rebecca Barty

**Contact details**  
Clinical Research Coordinator  
McMaster Transfusion Research Program  
McMaster University Faculty of Health Sciences Department of Medicine  
HSC-3H50  
1280 Main Street West  
Hamilton  
Canada  
L8S 4K1  
+1 (0)905 525 9140 ext. 22945  
bartyr@mcmaster.ca

**Type(s)**  
Scientific

**Contact name**  
Dr John Eikelboom

**Contact details**  
Department of Medicine  
Hematology +Thromboembolism  
HHSC, Hamilton General Hospital  
Hamilton  
Canada  
L8L 2X2  
+1 (0)905 521 2100 x44768  
eikelbj@mcmaster.ca

# Additional identifiers

## Protocol serial number

Sept122011

# Study information

## Scientific Title

INforming Fresh versus Old Red cell Management (INFORM): a large simple phase III randomized controlled trial

## Acronym

INFORM

## Study objectives

The freshest available compared with standard-issue blood reduces mortality.

Pilot study registered under ISRCTN38768001.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

1. Hamilton Health Sciences/Faculty of Health Sciences, Research Ethics Board, 16/08/2011
2. Southern Adelaide Clinical Human Research Ethics Committee, 15/08/2011
3. Cleveland Clinic, Institutional Review Board, 11/06/2012
4. St Joseph's Healthcare, Research Ethics Board, 17/05/2012

## Study design

Multi-centre international randomized controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Red blood cell transfusion

## Interventions

Patients requiring red blood cell transfusion will be randomized to one of the following conditions:

1. Freshest available red blood cells (experiment arm)
2. Standard-issue (oldest product compatible in stock) red blood cells available (control arm)

Both arms (experiment and control) are within standard care

The participant will not be contacted during this study. The decision to transfuse is determined by the patient's doctor. Once the ward orders the blood, the Transfusion Medicine Service will randomly allocate the patient to receive either the freshest available or standard-issue blood.

The patient's data will be collected electronically. An information brochure will be distributed to the patient so they are made aware of the study.

**Intervention Type**

Biological/Vaccine

**Phase**

Phase III

**Primary outcome(s)**

In-hospital mortality

**Key secondary outcome(s)**

Time to event (death)

**Completion date**

20/11/2015

**Eligibility****Key inclusion criteria**

All adult patients (age  $\geq 18$ ) will be included if:

1. Hospitalized at a participating centre (in-patient)
2. Undergoing a red cell transfusion

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Specific requirement for fresh blood (e.g., sickle cell disease, transfusion-dependent thalassemia, fresh cells ordered by care provider)
2. Pre-planned directed or autologous donation
3. Request for un-crossmatched blood
4. Anticipated massive transfusion as communicated from clinical area

**Date of first enrolment**

02/04/2012

**Date of final enrolment**

30/09/2015

**Locations****Countries of recruitment**

Australia

Canada

Israel

United States of America

**Study participating centre**

**Hamilton General Hospital**

Canada

-

**Study participating centre**

**Juravinski Hospital**

Canada

-

**Study participating centre**

**Flinders Medical Centre**

Australia

-

**Study participating centre**

**St Joseph's Healthcare Hamilton**

Canada

-

**Study participating centre**

**Cleveland Clinic**

United States of America

-

**Study participating centre**  
Meir Medical Center  
Israel  
-

## Sponsor information

**Organisation**  
McMaster University (Canada)

**ROR**  
<https://ror.org/02fa3aq29>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Canadian Institutes of Health Research (CIHR) (Canada)

**Alternative Name(s)**  
Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
Canada

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	17/11/2016		Yes	No
<a href="#">Protocol article</a>	protocol	01/01/2016		Yes	No
<a href="#">Other publications</a>	secondary analysis	01/11/2017		Yes	No